no of cases |
Sensitivity (%) at 80% specificity |
Sensitivity (%) at 90% specificity | AUC (95% CI) |
Best cut off value | |
All cases: | |||||
Clinicians' scores | 133 | 66 | 62 | 0.78 (0.70–0.85) | 1 |
CDT | 150 | 43 | 35 | 0.67 (0.59–0.75) | 5.4 |
GT | 158 | 26 | 25 | 0.57 (0.49–0.65) | 44 |
ASAT | 157 | 40 | 30 | 0.67 (0.59–0.74) | 26 |
ALAT | 157 | 25 | 21 | 0.63 (0.55–0.70) | 28 |
ASAT/ALAT ratio | 148 | 17 | 4 | 0.54 (0.45–0.62) | 0.79 |
Men: | |||||
Clinicians' scores | 75 | 72 | 69 | 0.84 (0.73–0.91) | 0 |
CDT | 83 | 62 | 48 | 0.78 (0.67–0.83) | 6.6 |
GT | 83 | 31 | 31 | 0.58 (0.46–0.69) | 112 |
ASAT | 82 | 37 | 31 | 0.66 (0.54–0.76) | 25 |
ALAT | 82 | 28 | 23 | 0.63 (0.51–0.73) | |
ASAT/ALAT ratio | 82 | 17 | 9 | 0.54 (0.46–0.63) | 0,76 |
Women: | |||||
Clinicians' scores | 59 | 55 | 50 | 0.71 (0.58–0.82) | 1 |
CDT | 71 | 28 | 22 | 0.52 (0.40–0.64) | |
GT | 75 | 17 | 6 | 0.51 (0.39–0.63) | |
ASAT | 75 | 50 | 28 | 0.66 (0.54–0.77) | 26 |
ALAT | 75 | 22 | 17 | 0.57 (0.45–0.69) | 26 |
ASAT/ALAT ratio | 75 | 11 | 6 | 0.58 (0.46–0.70) | 0.86 |
AUC= Area under the ROC curve.